Holly Foot

Holly Foot

Auto-generated profile, based on publicly available information

Holly Foot

The School of Pharmacy and Pharmaceutical Sciences, The University of Queensland, 20 Cornwall Street, Woolloongabba, Brisbane, Queensland, 4102, Australia

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2016 in Patient Education and Counseling
Verified
Journal Article
Closed access
HFHolly Foot
Holly Foot
ACAdam La Caze
Adam La Caze
GGGina Gujral
Gina Gujral
NCNeil Cottrell
Neil Cottrell

1 June 2022 in Research in Social and Administrative Pharmacy
Verified
Journal Article
Closed access
HFHolly Foot
Holly Foot
ISIan Scott
Ian Scott
NSNancy Sturman
Nancy Sturman
JWJennifer A. Whitty
Jennifer A. Whitty
KRKylie Rixon
Kylie Rixon
CFChristopher Freeman
Christopher Freeman

13 July 2023 in Exploratory Research in Clinical and Social Pharmacy
Verified
Journal Article
Open access
JCJaclyn Costello
Jaclyn Costello
MBMichael Barras
Michael Barras
HFHolly Foot
Holly Foot
NCNeil Cottrell
Neil Cottrell
Clinical pharmacists have been shown to identify and resolve medication related problems post-discharge, however the impact on patient clinical outcomes is unclear. To undertake a systematic review to identify, critically appraise and present the evidence on post-discharge hospital clinics that provide clinical pharmacist medication review; report the patient clinical outcomes measured; and describe the activities of the clinical pharmacist. Published studies evaluating a patient clinical outcome following a post-discharge hospital clinic pharmacy service were included. All studies needed a comparative design (intervention vs control or comparator). Pubmed, Embase, CINAHL, PsycnINFO, Web of Science, IPA and APAIS-Health databases were searched to identify studies. The type of clinic and the clinical pharmacist activities were linked to patient clinical outcomes. Fifty-seven studies were included in the final analysis, 14 randomised controlled trials and 43 non-randomised studies. Three key clinic types were identified: post-discharge pharmacist review alone, inpatient care plus post-discharge review and post-discharge collaborative clinics. The three main outcome metrics identified were hospital readmission and/or representation, adverse events and improved disease state metrics. There was often a mix of these outcomes reported as primary and secondary outcomes. High heterogeneity of interventions and clinical pharmacist activities reported meant it was difficult to link clinical pharmacist activities with the outcomes reported. A post-discharge clinic pharmacist may improve patient clinical outcomes such as hospital readmission and representation rates. Future research needs to provide a clearer description of the clinical pharmacist activities provided in both arms of comparative studies.

1 March 2019 in Patient Education and Counseling
Verified
Journal Article
Closed access
HFHolly Foot
Holly Foot
ACAdam La Caze
Adam La Caze
PBPeter Baker
Peter Baker
NCNeil Cottrell
Neil Cottrell

26 April 2025 in International Journal of Clinical Pharmacy
Verified
Journal Article
Open access
PDF file
JCJaclyn Costello
Jaclyn Costello
MBMichael Barras
Michael Barras
CSCentaine L. Snoswell
Centaine L. Snoswell
HFHolly Foot
Holly Foot
Background: Patients transitioning from secondary to primary healthcare are at increased risk of medication errors, adverse drug events and readmission to hospital. Incorporating a post-discharge follow-up by a hospital pharmacist has been proposed as a potential strategy to reduce readmissions. Aim: To determine the impact of a hospital-based pharmacist-led post-discharge medication review clinic on 30-day hospital readmissions in adult patients. Method: A single-site, retrospective cohort study compared the medical records of patients who attended the Pharmacist Review and EValuation of Existing and New Therapies (PREVENT) clinic between 1 January 2018 and 31 December 2019 to a group of case-matched control patients who did not attend the clinic. Patient inclusion criteria comprised those 18 years and older and attended the PREVENT clinic within 30 days of discharge. The matched group was based on gender, age and hospital metrics. The primary outcome measure is unplanned, all-cause 30-day hospital readmission. Results: There were 170 patients per group, with similar baseline characteristics. There were significantly less unplanned all-cause 30-day hospital readmissions in the PREVENT clinic group (n = 12 (7.1%)) compared to the control group (n = 40 (23.5%), χ2 = 17.799, p < 0.001). Conclusion: This study demonstrates that a hospital-based pharmacist-led post-discharge medication review clinic reduced 30-day hospital readmissions in adult patients compared to a group of case-matched controls. This study provides evidence to support extending pharmaceutical care beyond the inpatient hospital setting into the early post-discharge period, particularly in hospitals providing comprehensive clinical pharmacy services.

13 April 2017 in BMJ Open
Verified
Journal Article
Open access
PDF file
HFHolly Foot
Holly Foot
CFChristopher Freeman
Christopher Freeman
KHKarla Hemming
Karla Hemming
ISIan Scott
Ian Scott
ICIan D Coombes
Ian D Coombes
NCNeil Cottrell
Neil Cottrell
Introduction A model of general practitioner (GP) and pharmacist collaboration in primary care may be an effective strategy to reduce medication-related problems and provide better support to patients after discharge. The aim of this study is to investigate whether a model of structured pharmacist and GP care reduces hospital readmissions in high-risk patients. Methods and analysis This protocol details a stepped-wedge, cluster-randomised trial that will recruit participants over 9 months with a 12-month follow-up. There will be 14 clusters each representing a different general practice medical centre. A total of 2240 participants will be recruited from hospital who attend an enrolled medical centre, take five or more long-term medicines or whose reason for admission was related to heart failure or chronic obstructive pulmonary disease. The intervention is a multifaceted service, involving a pharmacist integrated into a medical centre to assist patients after hospitalisation. Participants will meet with the practice pharmacist and their GP after discharge to review and reconcile their medicines and discuss changes made in hospital. The pharmacist will follow-up with the participant and liaise with other health professionals involved in the participant’s care. The control will be usual care, which usually involves a patient self-organising a visit to their GP after hospital discharge. The primary outcome is the rate of unplanned, all-cause hospital readmissions over 12 months, which will be analysed using a mixed effects Poisson regression model with a random effect for cluster and a fixed effect to account for any temporal trend. A cost analysis will be undertaken to compare the healthcare costs associated with the intervention to those of usual care. Ethics and dissemination The study has received ethical approval (HREC/16/QRBW/410). The study findings will be disseminated through peer-reviewed publications, conferences and reports to key stakeholders. Trial registration number ACTRN12616001627448